To evaluate the effects of the sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin added to metformin for 12 weeks in patients with type 2 diabetes.This dose-ranging, double-blind, placebo-controlled trial randomized 495 participants with type 2 diabetes inadequately controlled on metformin [haemoglobin A1c (HbA1c) >7 to ≤10
作者：J, Rosenstock；L J, Seman；A, Jelaska；S, Hantel；S, Pinnetti；T, Hach；H J, Woerle
来源：Diabetes, obesity & metabolism 2013 年 15卷 12期
